p53 is a key regulator in cell apoptosis, and cancer cells deficient in p53 expression fail to respond to chemotherapy. Here we show that effective Doxorubicin (DOX)-induced apoptosis is,p53-dependent. However, an alternative treatment of DOX/TNF-alpha/DOX restored sensitivity of p53-deficient cells to DOX-induced apoptosis. Treatment of cells with TNF-alpha resulted in a decrease of p21 (waf1/cip1/sdi1) expression following second dose of DOX. In previous work, we demonstrated that p21 suppressed DOX-induced apoptosis via its (cyclin-dependent kinase) CDK-binding and CDK-inhibitory activity. Thus, we propose that TNF-a enhances the anti-cancer effect of DOX through suppressing the anti-apoptotic activity of p21, and that a combined treatment TNF-alpha/Dox is an effective chemotherapeutic strategy for p53-deficient cancers. (c) 2005 Elsevier Inc. All rights reserved.
机构:
Ctr Rech Cordeliers, Equipe 19, INSERM, Mort Cellulaire Programmee,U872, Paris, France
Univ Paris 06, Paris, France
Univ Paris 05, Paris, FranceUniv Zaragoza, Fac Ciencias, Dept Bioquim Biol Mol & Celular, E-50009 Zaragoza, Spain